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Manual Scalp Cooling in Early Stage Breast Cancer: 
Value of Caretaker Training and Patient-Reported Experience to Optimize Efficacy and Patient Selection
Manaz Rezayee, Nicole Moxon R.N., Staci Mellinger R.N., Amanda Y. Seino, Nicole E. Fredrich, Tracy L. Kelly, Susan Mulligan M.A., Patrick Rossi M.D., Ijeoma Uche M.D., Walter J. Urba M.D. Ph.D., Alison K. Conlin M.D. M.P.H., Janet Ruzich D.O., David B. Page M.D.
Background
Standardized Training: 
• Prior to commencing therapy, one or more caretaker(s) were designated to assist with cold capping and underwent 
standardized training by certified research staff.
• Training included didactic and hands-on simulation to optimize proper cold capping use and technique.  
• Participants were provided structured training prior to the first treatment, but were not provided additional training or support 
during the remainder of treatment. 
• Cold-cap temperatures determined by hair type (fine/medium hair: -28°C to -30°C; thick hair: -30°C to -32°C). 
Primary Endpoint: 
o 30-day post-treatment hair retention using the Dean’s alopecia score (<50% hair loss, score 0-2 on 5-point scale)
Results
• 12 patients were enrolled and underwent training; 2 patients withdrew consent before initiating treatment (10 evaluable patients).
Efficacy: Scalp Cooling, Hair Loss and Safety
• 80% (n=8/10) of evaluable patients achieved the primary efficacy endpoint of <50% hair loss with Dean’s Alopecia scores of 0-
2 (Table 1). Trial failures reported in 2 patients (20%) due to pre-mature treatment discontinuation. 
• Patient-reported head cover usage (scarf/hat) for concealing hair loss was reported in only 1 patient (ACT; Dean’s Score: 2).
• Only 1 (out of 16; 6.25%) adverse event was possibly related to cold-capping (grade 1 head sore).
Secondary Endpoint: PROs 
• As expected with chemotherapy, declines in global health status were observed; however, post-treatment global health 
estimates are numerically favorable relative to estimates from other published cold cap studies. 
• We observed an improvement in emotional function and future perspective (BR-23) at post-treatment visit relative to baseline. 
• Notable improvements measured at time of exit interview were also seen in physical, role, and social functioning. 
Exploratory Endpoint: Exit Interviews
• 80% (n=8/10) participated in the optional exit interview, including one subject who had prematurely discontinued cold-capping. 
• All subjects(100%; n=8/8) mentioned importance of the training session, specifically the hands-on portion with majority (62.5%; 
n=5/8) believed success was dependent on training session and cold caps were safe, effective and feasible (75%; n=6/8). 
• Majority (87.5%; n=7/8) speculated QOL would decrease without capping citing less community support/social interactions, 
hair loss (“chemo head”), financial, and negative impacts on career, privacy, self-esteem, and self-image.
• We analyzed the interview responses to identify thematic effects of cold-capping that could be dichotomized as beneficial 
versus harmful (Figure 2). Prevalent themes identified included: privacy, perception (self-image/identity), distraction from cancer, 
dependence on others and practical resources). 
• These effects were then used to develop a clinical instrument to inform patients of the subjective costs and benefits of cold-
capping (figure 3). 
Arm Regimen Final Dean’s Alopecia Score Efficacy Point Estimate (95% CI)
Arm 1
n = 3
ACT/HP
0: 1/3 (33.3%) 
1: 1/3 (33.3%)
2: 1/3 (33.3%)
1.0
Arm 2
n = 5
TCH/P
0: 2/5 (40%)
1: 2/5 (40%)
2: 1/5 (20%)*
0.8
Arm 3
n = 1
TC 2: 1/1 (100%)* 0.0
Arm 4
n = 1
T/H 0: 1/1 (100%) 1.0
Total: 
n = 10
0: 4/10 (40%)
1: 3/10 (30%)
2: 3/10 (30%)*
0.8
A) TCH/P B) ACT/HP C) ACT/HP
• Chemotherapy-induced alopecia (CIA) is a common and emotionally distressing adverse effect of curative-intent chemotherapy 
regimens in early stage breast cancer, resulting in physical and psychological impact on quality of life (1, 2) 
• Potential mechanism of action is thought to be associated with reduced chemotherapy exposure related to local vasoconstriction, 
and/or direct metabolic effects on hair follicle. (1, 2)
• Although FDA-approved machine-based scalp cooling devices, such as the Paxman® and DigniCap® systems, is effective for 
reduction and/or prevention of CIA; however, availability is geographically limited. (3, 4)
• Manual cold-cap based systems are alternative systems that may also be effective (64.7%; n=55/85) and can be accessed by 
motivated patients regardless of geographic location. (5)
• In prospective trials of manual cold capping, dedicated research staff have been responsible for cold-cap implementation, 
whereas there are limited prospective data on outcomes in real-world settings. (1,5)
What is Penguin Cold Cap? 
o Penguin Cold Cap is a portable scalp cooling system, which employs Crylon gel-filled caps that are cooled on dry ice, fitted 
onto the scalp, and exchanged every 20-30 minutes by a caretaker. 
• We evaluated the feasibility of caretaker-administered cold-cap efficacy following structured standardized training, and utilized 
patient-reported subjective outcomes to develop a clinical tool to facilitate patient selection.
Figure 1: Overview of Trial Process
Table 1: Final Dean’s Alopecia Score with 2 treatment 
discontinuations (ie trial failures) noted by asterisk.
Figure 1: Primary endpoint efficacy via photographs from different angles comparing 
baseline and the final post-treatment Dean’s Alopecia score with (A) 6 cycles of 
TCH/P chemotherapy, while (B) and (C) both received 8 cycles of ACT/HP. 
Table 2 (Below): Secondary endpoint assessment via patient-reported questionnaire 
results during 3 different instances (pre-treatment, post-treatment and exit interview) in 
this study and comparative QOL data obtained from other studies with absolute QOL 
mean values and calculated changes from baseline. Average follow-up at time of 
interview was 281 days (range: 30 to 548 days). High scores in global health status 
and functional scales represent better/higher QOL. Higher scores in symptom scales 
represent having higher symptoms (worse/lower QOL). 
• This pilot study affirms the safety and efficacy of manual cold-capping for the prevention of CIA in early stage 
breast cancer, and highlights its potential in the setting of both anthracycline-containing and anthracycline-sparing 
chemotherapy regimens. It also highlights the considerable costs and effort associated with cold-capping. 
• It also demonstrates the potential utility of structured training to maximize efficacy and patient satisfaction. 
• Selected patients with early stage breast cancer may benefit subjectively from cold-capping. In cataloguing the 
subjective cold-cap patient accounts, prevalent themes potentially contributing to the determination of clinical 
benefit versus harm were identified. 
• Using these observations, we propose a clinical decision-making tool that may enable patients to weigh the 
subjective benefits and drawbacks of cold-capping, so patients can make informed decisions regarding cold-cap 
implementation. 
• Further research is necessary to validate our preliminary findings, and to further define the utility of the cold-
capping decision-making tool. 
Figure 2: Representation of prevalent themes of effects of preventing 
and/or reducing CIA via cold-capping identified during post-treatment exit 
interviews. 
A small pilot study (n=10) was conducted to evaluate the feasibility and efficacy of manual cold-capping.
Key eligibility criteria included: 
• ≥18 years of age and informed consent
• No hair loss at baseline (Dean’s score 0); 
• No pre-existing scalp condition; 
• Planned chemotherapy (ACT/HP, TC, 
TCHP, or TH); and 
• Availability of caretaker(s) for cold-capping
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Prior to Day 1
• Caretaker 
Training 
Session
• QLQ-C30
• BR-23
• BIS
Day 1 (Prior to 
Infusion):
• Photography
• Cold cap 50 
minutes prior
• Dean’s 
Alopecia 
Scale
• CTCAE v4.0
30-Day Post-
Treatment
• Photography
• Dean’s 
Alopecia 
Scale
• QLQ-C30
• BR-23
• BIS
• WIWI? 
• CTCAE v4.0
Post-Treatment 
Exit Interview
• Short 
interview
• QLQ-C30
• BR-23
• BIS
• WIWI?
Secondary Endpoints:
• Patient-reported outcomes:
o QOL assessments:
Ø Was it Worth it? (WIWI?)
Ø EORTC QLQ-C30
Ø QLQ-BR23
Ø Body Image Scale (BIS)
o CTCAE v4.0 toxicity and patient-reported wig/head cover use
o Subjective patient experience (obtained by standardized exit interviews. 
Statistical Design: 
o Primary outcome was reported as the proportion of efficacy-evaluable subjects who retained >50% of their hair at 30 
days post-treatment (Dean’s scale 0-2).
o Modified intention-to-treat (ITT) analysis whereby all subjects receiving at least 75% of prescribed chemotherapy dose 
were considered evaluable. 
o No pre-defined thresholds were set for declaring success as this was a pilot assessment to collect objective and 
subjective data. 
o Paired 2-sample t-tests (5% two-way alpha) were conducted to identify significant deviations in the mean, with the intent 
of obtaining descriptive data, therefore no corrections were made for multiple comparisons.
Conclusion
References
1. Pre-Cooling
• Starts 50 minutes 
prior to infusion.
• Cap change every 
20 minutes x 2.
2. Infusion
• Cap change every 
30 minutes
3. Post-Infusion
• Caps change 
every 30 minutes 
for 4 hours.
Results
Figure 2: Patient Experience with Cold Caps Every Treatment Day
Absolute Mean Absolute Change
Subset
This Study Other Studies This Study Other Studies
Pre-Tx Post-Tx Exit Interview Paxman Sc
a,8 DigniCap SCb,7 Pre- to Post Tx No SC (CT MLS)c,6 DigniCap SCb,7SC & no wig SC & wig Baseline 4th cycle
QLQ-
C30
Global Health Status 70.83 69.17 64.58 68.5 60.3 70.1 65.7 -1.66 -1.80 -4.4
Functional Scale
Physicald
Role
Emotionald
Cognitive
Social
94
80
70
83.33
81.67
77.34
56.67
79.17
68.33
68.33
84.17
77.08
69.79
64.58
70.84
77.9
62.0
72.1
72.4
79.7
70.7
52.2
67.8
65.0
71.7
93.4
85.7
70.7
90.4
83.0
86.1
82.0
69.0
82.8
73.4
-16.66
-23.33
9.17
-15
-13.34
-7.40
-3.89
6.73
-6.50
-5.35
-7.3
-3.7
-1.7
-7.6
-9.6
Symptom Scale
Financial Difficulties 26.67 23.33 33.33 13.5 18.9 --- --- -3.34 2.49 ---
QLQ-
BR23
Functional Scales
Body Image
Future Perspective
71.67
33.33
67.5
46.67
64.58
41.67
74.2
53.8
65.3
52.2
76.9
48.9
66.0
59.6
-4.17
13.34
-15.24
12.14
-10.9
10.7
Symptom Scale
Upset by Hair Lossd 3.33 30 4.17 21.8 43.7 19.4 38.9 26.67 14.38 19.5
a Although this study did indicate collecting QOL data prior to chemotherapy, baseline data was not provided and it was reported that no statistical differences were found between with and 
without scalp cooling (SC), except for cognitive functioning in QLQ-C30 (85.9 vs 80.7; p=0.05).
b This study focused on patients receiving an adjuvant treatment with anthracycline.
c This study utilized a model-derived statistical analysis for the QOL data and provided the mean least square (MLS) differences between time of diagnosis and 2-year post-diagnosis visit.
d Paired two-sample t-test between baseline and 30-day post-treatment demonstrated statistical significance (<0.05).
Privacy
Perception 
(Self-Image/Identity)
Distraction from 
Cancer
Dependence on 
Others
Practical Resources
Effects of Preventing/Reducing CIA via Cold-Capping
Positive and/or Beneficial Negative and/or Unfavorable
Forms of invasion of privacy via: 
• Constantly being touched
• Public cap changes
Forms of preservation of privacy via: 
• Appearance (keeping hair) 
• Concealing diagnosis until ready
•Ability to reverse refusal of chemotherapy
• Financial stability via ability to maintain career
•Normal social interactions 
• Improved emotional and/or social well-being
•Ability to share when ready and willing
• Became more self-conscious 
• Decreased confidence
Control and continue “normal” life due to 
ability to conceal diagnosis
Emotionally and/or physically exhausting to 
endure long cold-capping process in addition 
to treatment and may feel a lack of control
The only positive part of the whole process
• Conceal until ready and ability to choose resulting in:
• Improved emotional and/or mental well-being
• Prioritize self and ask for help when needed
• Improve self-esteem, image and confidence
• Decrease in self-consciousness
• Maintain career resulting in improved financial health
• ”Normal” perception:
• Inclined to be more social (increased social interactions)
• Helps to cope and maintain hope and strength
• Lack of change in life 
• May be more stressful and anxiety provoking to 
undergo this long and extensive process 
• Negative impacts due to the repetitious nature of 
cold-capping and/or decreased self-confidence
Diverted focus away from treatment
• Couldn’t move on and/or grieve as hair loss 
(thinning) occurs throughout 
• More self-conscious and decreased self-confidence 
• Additional stress and/or anxiety 
• Discomfort in the beginning 
• Disagreements with research staff
• Establishing “normal” appearance and/or helping cope with 
diagnosis
• Better prioritize self and ask for help when needed
• Increased social interaction
• Ability to ignore diagnosis 
• Obtain a bit of control over life
Increased social interaction and established 
a sense of belonging and/or community
• Presence of additional and consistent family support
• Support that may have otherwise been lacking
• Family felt useful in helping with battle against cancer 
• Helps to cope and maintain hope and strength
• Better prioritize self and ask for help when needed
Difficulty obtaining help due to huge 
commitment
• May feel like bothering others just to help you
• May put negative pressure on caretakers and cause 
them to be overwhelmed, stressed or anxious
• Finding right person (detail-oriented with physical 
strength)
These are necessary throughout the whole process regardless of the impact: 
• Atleast 1 designated caretaker available at all infusions
• Financial planning to ensure all costs are covered because it is costly
• Someone to pick up dry ice prior to chemotherapy infusion
• Having enough and/or dedicated space designated for cold-capping
Would Cold-Capping Therapy Be Appropriate For You? 
No YesPrivacy
Distraction from Cancer
Perception (Self-Image/Identity)
Dependence on Others
Practical Resources
Is it important for you to conceal your diagnosis? 
Do you find it important to share your diagnosis with others when you are ready to?
Are you okay with people frequently touching your head to help put the cold-cap on? 
Are you okay with the possibility of others observing you because of increased attention as a 
result of cold-capping? 
Due to regularly being touched and/or public cap changes, you may become more self-
conscious and/or anxious with a potential decrease in confidence. Are you okay with 
having these forms of invasion of privacy in order to preserve your hair? 
Do you have at least one designated caretaker  or local consultant capable of cold-capping to 
attend all infusion sessions? 
Do you have the financial funds necessary to proceed with Cold-Cap Therapy?
If necessary, do you have additional support to pickup dry ice the night prior to infusion?
Are you okay with completely depending on your caretaker for cold-capping as it is shown to 
be impacted by caretaker technique?
Do you think having additional caretaker support in this regard will help you?
Do you think in keeping your hair you may feel “normal?”
Do you think your appearance impacts how you feel (when you look better you feel better)?
Do you think in looking “normal” you may obtain the ability to continue working? 
Do you think preserving your hair will help you cope with a cancer diagnosis?
Do you think in keeping your hair you may feel like you have some control over your life? 
Do you think focusing on cold-capping instead of treatment will help you in the process of 
grieving and/or moving on? 
If you were to lose your hair, would you more easily convince yourself to stay home instead 
of going out? 
Figure 3: Clinical instrument assessing 
appropriateness for patient to pursue cold-capping.
